Abstract
p53, the “guardian of the genome” and the most mutated gene in cancer presents a considerable therapeutic opportunity as well as a challenge. In the past decade, several therapeutic strategies have been developed that aim to take advantage of a wealth of knowledge about p53, including insights into the biology and patho-biology of p53. Nevertheless, considerable challenges remain, not least as a result of tissue- and cancer-specific differences in p53 regulation and/or function. p53 does not act in the same manner in all tissues or in the cancers arising from them. Nor is p53 regulated in the same way in the wide variety of tissues from which cancers develop. Therefore, potential strategies for therapeutic targeting need to be tailored to each tumour/tissue type. This review summarises some of these tissue- and cancer-specific issues to suggest how different strategies are required for cancers arising from different tissues and to illustrate the complexities of therapeutic targeting of p53.
Keywords: p53, MDM2, cancer, therapy, apoptosis, senescence, colorectal cancer, renal cancer, oropharyngeal squamous cell carcinoma, hepatocellular carcinoma, hepatitis B virus, human papilloma virus, Nutlin-3, MI-219, MI-319, PRIMA, small molecule inhibitors, tissues
Current Pharmaceutical Design
Title: Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All
Volume: 17 Issue: 6
Author(s): Nikolina Vlatkovic, Kerryanne Crawford, Carlos P. Rubbi and Mark T. Boyd
Affiliation:
Keywords: p53, MDM2, cancer, therapy, apoptosis, senescence, colorectal cancer, renal cancer, oropharyngeal squamous cell carcinoma, hepatocellular carcinoma, hepatitis B virus, human papilloma virus, Nutlin-3, MI-219, MI-319, PRIMA, small molecule inhibitors, tissues
Abstract: p53, the “guardian of the genome” and the most mutated gene in cancer presents a considerable therapeutic opportunity as well as a challenge. In the past decade, several therapeutic strategies have been developed that aim to take advantage of a wealth of knowledge about p53, including insights into the biology and patho-biology of p53. Nevertheless, considerable challenges remain, not least as a result of tissue- and cancer-specific differences in p53 regulation and/or function. p53 does not act in the same manner in all tissues or in the cancers arising from them. Nor is p53 regulated in the same way in the wide variety of tissues from which cancers develop. Therefore, potential strategies for therapeutic targeting need to be tailored to each tumour/tissue type. This review summarises some of these tissue- and cancer-specific issues to suggest how different strategies are required for cancers arising from different tissues and to illustrate the complexities of therapeutic targeting of p53.
Export Options
About this article
Cite this article as:
Vlatkovic Nikolina, Crawford Kerryanne, P. Rubbi Carlos and T. Boyd Mark, Tissue-Specific Therapeutic Targeting of p53 in Cancer: One Size Does Not Fit All, Current Pharmaceutical Design 2011; 17 (6) . https://dx.doi.org/10.2174/138161211795222568
DOI https://dx.doi.org/10.2174/138161211795222568 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effects of Micro RNAs and their Targets in Periodontal Diseases
Infectious Disorders - Drug Targets Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer
Current Medicinal Chemistry Exploration of Chemopreventive Potential of Linalool in Targeting Lung Cancer Biomarkers
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Drug-Induced Pulmonary Complications in Cancer Patients You Can Save Life!
Current Respiratory Medicine Reviews The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Phenothiazine Derivatives as Potential Antiproliferative Agents: A Mini- Review
Mini-Reviews in Organic Chemistry Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry PI-3-Kinase Inhibitors in Colorectal Cancer
Current Cancer Drug Targets Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Porphyrins as Radiosensitizing Agents for Solid Neoplasms
Current Pharmaceutical Design Editorial (Thematic Issue: Current Research and Clinical Application in Head and Neck Radiotherapy)
Current Cancer Therapy Reviews Imaging Features of Carcinosarcoma Arising from Adenofibroma of the Uterus: A Case Report
Current Medical Imaging The Promise of Antimicrobial Peptides for Treatment of Human Schistosomiasis
Current Drug Targets Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design Effect of Lapachol on the Inhibition of Matrix Metalloproteinase Related to the Invasion of Human Fibrosarcoma Cells
Current Molecular Pharmacology Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Cyclooxygenase Enzymes: Regulation and Function
Current Pharmaceutical Design